drugset / Trial / NCT00818363

A Safety and Effectiveness Study of SABER®-Bupivacaine for Pain Following Shoulder Surgery

NCT00818363

Phase 2 Completed 60 enrolled Durect Nycomed · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a research study testing SABER-Bupivacaine (an experimental pain-relieving medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common local anesthetic, for a few days in order to treat local post-surgical pain. The purpose of this study is to investigate safety (if there are any side effects) associated with the use of SABER-Bupivacaine and how well it works in reducing pain and opioid-related side effects following shoulder surgery.

Timeline

Start
2008-12
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 5 ml Other

Indications

No indication recorded.